<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37781520</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1449-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>15</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>International journal of biological sciences</Title><ISOAbbreviation>Int J Biol Sci</ISOAbbreviation></Journal><ArticleTitle>Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment.</ArticleTitle><Pagination><StartPage>4948</StartPage><EndPage>4966</EndPage><MedlinePgn>4948-4966</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ijbs.86632</ELocationID><Abstract><AbstractText>A high recurrence rate of non-Hodgkin's lymphoma (NHL) following chimeric antigen receptor T (CAR T) cell treatment remains a bottleneck, and immunosuppressive tumor microenvironment (TME) compromising CAR T cell efficacy in NHL is the primary cause of relapse. Accordingly, modifying the structure of CAR T cells to attenuate the inhibitory effect of TME thus reducing recurrence rate is a valuable research topic. CD47 has been proved to be a promising therapeutic target and is crucial in regulating macrophage function. Herein, we engineered CD19-CAR T cells to secrete an anti-CD47 single-chain variable fragment (scFv) and validated their function in enhancing antitumor efficacy, regulating T cells differentiation, modifying phagocytosis and polarization of macrophages by <i>in vitro</i> and <i>in vivo</i> researches. The efficacy was analogous or preferable to the combination of CAR T cells and CD47 antibody. Of note, anti-CD47 scFv secreting CAR T cells exert a more potent immune response following specific antigen stimulation compared with parental CAR T cells, characterized by more efficient degranulation and cytokine production with polyfunctionality. Furthermore, locally delivering anti-CD47 by CAR T cells potentially limits toxicities relevant to systemic antibody treatment. Collectively, our research provides a more effective and safer CAR T cell transformation method for enhancing tumor immunotherapy.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Yingqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Peiyun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jianyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yuxing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Honghao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhongwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Manxiong</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yulu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meifang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, Guangdong, 510005, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Biol Sci</MedlineTA><NlmUniqueID>101235568</NlmUniqueID><ISSNLinking>1449-2288</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057127">Single-Chain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051928">CD47 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076962">Receptors, Chimeric Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497894">CD47 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057127" MajorTopicYN="Y">Single-Chain Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051928" MajorTopicYN="N">CD47 Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076962" MajorTopicYN="Y">Receptors, Chimeric Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD47</Keyword><Keyword MajorTopicYN="N">Chimeric antigen receptor T cell</Keyword><Keyword MajorTopicYN="N">Non-Hodgkin's lymphoma</Keyword><Keyword MajorTopicYN="N">T cell polyfunctionality</Keyword><Keyword MajorTopicYN="N">macrophage</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37781520</ArticleId><ArticleId IdType="pmc">PMC10539696</ArticleId><ArticleId IdType="doi">10.7150/ijbs.86632</ArticleId><ArticleId IdType="pii">ijbsv19p4948</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127:2361&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27069255</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Liu J, Song Y, Wang X, Zhou M, Wang L. et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019;12:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399942</ArticleId><ArticleId IdType="pubmed">30832702</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV. et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278156</ArticleId><ArticleId IdType="pubmed">30514386</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28:678&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9305718</ArticleId><ArticleId IdType="pubmed">35440724</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Tu S, Wang C, Huang R, Deng L, Song C. et al. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Front Immunol. 2020;11:564099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731732</ArticleId><ArticleId IdType="pubmed">33329526</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882485</ArticleId><ArticleId IdType="pubmed">29226797</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP. et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30501490</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopken UE, Rehm A. Targeting the Tumor Microenvironment of Leukemia and Lymphoma. Trends Cancer. 2019;5:351&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">31208697</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood. 2018;131:2621&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6032892</ArticleId><ArticleId IdType="pubmed">29728402</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Y, Chen T, Hu R, Zhu R, Li C, Ruan Y. et al. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res. 2021;9:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8501632</ArticleId><ArticleId IdType="pubmed">34625124</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. Adv Mater. 2020;32:e2002054.</Citation><ArticleIdList><ArticleId IdType="pubmed">32856350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian Z, Shi L, Guo YL, Lv Z, Tang C, Niu S. et al. Cd47-Sirpalpha interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells. Proc Natl Acad Sci U S A. 2016;113:E5434&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027463</ArticleId><ArticleId IdType="pubmed">27578867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017. 9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28298418</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, Montes-Servin E, Herrera-Martinez M. et al. CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br J Cancer. 2017;117:385&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5537491</ArticleId><ArticleId IdType="pubmed">28632731</ArticleId></ArticleIdList></Reference><Reference><Citation>Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N. et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med. 2018;379:1711&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058634</ArticleId><ArticleId IdType="pubmed">30380386</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14:180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557524</ArticleId><ArticleId IdType="pubmed">34717705</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Hu Y, Ye T, Chen Y, Zhou L, Li F. et al. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng. 2021;5:414&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">33046865</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25008267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F. et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">29319160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118:4890&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208297</ArticleId><ArticleId IdType="pubmed">21828138</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP. et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther. 2013;21:1919&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808133</ArticleId><ArticleId IdType="pubmed">23774794</ArticleId></ArticleIdList></Reference><Reference><Citation>Egelston CA, Avalos C, Tu TY, Simons DL, Jimenez G, Jung JY. et al. Human breast tumor-infiltrating CD8(+) T cells retain polyfunctionality despite PD-1 expression. Nat Commun. 2018;9:4297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191461</ArticleId><ArticleId IdType="pubmed">30327458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31477906</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123:3750&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055922</ArticleId><ArticleId IdType="pubmed">24782509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, Zhang L, Zhang H, Ning J, Tu S, He Y. et al. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia. Cytotherapy. 2019;21:659&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31031152</ArticleId></ArticleIdList></Reference><Reference><Citation>Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767569</ArticleId><ArticleId IdType="pubmed">34624224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kewcharoenwong C, Prabowo SA, Bancroft GJ, Fletcher HA, Lertmemongkolchai G. Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization. Front Immunol. 2018;9:2109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6157405</ArticleId><ArticleId IdType="pubmed">30283449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A. et al. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clin Cancer Res. 2021;27:2190&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33451977</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo F, Das JK, Kobayashi KS, Qin QM, T AF, Alaniz RC, Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment. J Immunother Cancer. 2022. 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8734016</ArticleId><ArticleId IdType="pubmed">34987022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R. et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63:7462&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14612546</ArticleId></ArticleIdList></Reference><Reference><Citation>Stock S, Schmitt M, Sellner L. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. Int J Mol Sci. 2019. 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6940894</ArticleId><ArticleId IdType="pubmed">31835562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126939</ArticleId><ArticleId IdType="pubmed">30102295</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Siriwon N, Zhang X, Yang S, Jin T, He F. et al. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Clin Cancer Res. 2017;23:6982&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">28912137</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>